Abstract:Triggering receptor expressed on myeloid cells-2 (TREM2), which is expressed on the surface of tumor-associated macrophages (TAMs), has been found to play a major role in the diagnosis and treatment of tumors. TREM2 expression is significantly upregulated in tumor tissues, and therefore, targeting TREM2 for tumor imaging may be of value. Previously, we performed TREM2 targeting imaging by using Ga-68-NOTA-COG1410 or a I-124-labeled monoclonal antibody (mAb) and F(ab ')(2) in mouse models of colon and gastric tumors. However, some of the shortcomings of these probes (i.e., the high uptake of Ga-68-NOTA-COG1410 in the liver, the difficulty of obtaining iodine-124, and the long half-life of iodine-124) have hindered their clinical use. Herein, we sought to synthesize novel molecular probes targeting TREM2 that are more conducive to clinical translation, eliminating the interference of isotope availability and in vivo probe biodistribution issues. Therefore, we established A549 cell lines with negative human TREM2 (hTREM2) expression (GFP tag; hTREM2(-) A549) or upregulated hTREM2 expression (GFP tag; hTREM2(+) A549) using lentiviral transfection and confirmed these with Western blotting and immunocytochemistry. We then prepared a mouse anti-human TREM2 (5-mAb) by immunizing with the hTREM2 antigen. The antibody fragments 5-F(ab ')(2) and 5-Fab were prepared from 5-mAb, and Tc-99m-MAG(3)-5-F(ab ')(2) and Tc-99m-MAG(3)-5-Fab were then synthesized with excellent stability and specificity. Tc-99m-MAG(3)-5-F(ab ')(2) had a slightly higher in vitro affinity than Tc-99m-MAG(3)-5-Fab (K-d = 3.32 +/- 0.05 nmol versus 4.62 +/- 0.85 nmol). Tc-99m-MAG(3)-5-F(ab ')(2) and Tc-99m-MAG(3)-5-Fab both showed excellent specificity: after adding a 100-fold precursor, the two probes binding to the cells were almost blocked. In vivo pharmacokinetics showed that the distribution and elimination half-lives of Tc-99m-MAG(3)-5-Fab (T-1/2 alpha = 1.25 +/- 0.30 min and T-1/2 beta = 21.98 +/- 2.80 min, respectively) were significantly reduced compared to those of Tc-99m-MAG(3)-5-F(ab ')(2) (T-1/2 alpha = 2.64 +/- 0.37 min and T-1/2 beta = 86.55 +/- 26.86 min, respectively). In micro single-photon emission computed tomography/computed tomography (micro-SPECT/CT) imaging, the tumor was clearly displayed at 1 h after Tc-99m-MAG(3)-5-Fab injection, while the blood background was extremely low at 3 h, and the probe was mainly excreted through the kidneys and biliary tract. Tc-99m-MAG(3)-5-F(ab ')(2) uptake was also detected at the tumor site, although the blood background was consistently high. The biodistribution results were consistent with the micro-SPECT/CT imaging results. Tc-99m-MAG(3)-5-Fab could clearly display hTREM2(+) A549 tumors in a short time (1 h) with low uptake in nontumor organs and tissues and thus has clinical application prospects.

Synthesis and Biodistribution of 99Tcm-MAG2-Ade as A Tumor Imaging Agent

Synthesis and Biodistribution of 99Mtc-Peptides Conjugated Adenine As Tumor Imaging Agents

2-Mercaptoacetylglycylglycyl (MAG2) As a Bifunctional Chelator for 99Mtc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics

99m TcO(MAG 2 -3G 3 -dimer): a new integrin α v β 3 -targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics

99Mtco(mag2-3G3-dimer): a New Integrin Αvβ3-Targeted SPECT Radiotracer with High Tumor Uptake and Favorable Pharmacokinetics

The preparation and biological evaluation of 99mTc-MAG3-glucose

A Novel Tc-99m-labeled and MAG<sub>3</sub>-chelated Arginine-Arginine-Leucine containing Peptide for Tumor Imaging in Hepatoma Xenografts Model

Biodistribution and Pharmacokinetics of 99tcm Labeled Carbohydrated Peptides in Mice Bearing Tumors

Synthesis of Labelled Small Peptide Complexes for Imaging Agents with Technetium-99M and Biodistribution in Mice.

Biodistribution and Imaging of 99m Tc-MAVGG-adenine in Tumor Bearing Mice

Synthesis and Biological Studies of 99m Tc(HYNIC–MFL)(tricine)(TPPTS) As a Novel Tumor Imaging Agent

Synthesis, Radiolabeling and in Vivo Biological Evaluation of 99Mtc-Labeled MAG3-based Bisnitroimidazole Complexes As Tumor Hypoxia Markers

SYNTHESIS OF LABELED PEPTIDE COMPLEXES WITH TECHNETIUM-99m AND BIODISTRIBUTION IN MICE

99Tcmn-Dgdtc,a New Glucose Metabolic Agent,the Pharmacokinetics and Imaging Results

Synthesis and single photon emission computed tomography imaging evaluation with 99mTc-labeled bevacizumab in colorectal cancer xenografts

Synthesis, Biodistribution and Quantitative Structure-Activity Relationship Studies of New 99mtc Labeled Pseudo-Peptide Complexes.

Synthesis of novel N3S pseudo-peptide and biodistribution of 99Tcm-pseudo-peptide complexes in mice

Preclinical Evaluation of <SUP>99m</SUP>Tc-MAG<sub>3</sub>-5-Fab Targeting TREM2 in Lung Cancer Mouse Models: A Comparison with <SUP>99m</SUP>Tc-MAG<sub>3</sub>-5-F(ab)<sub>2</sub>

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

<sup>99m</sup>Tc-Labeled Bombesin(7−14)NH<sub>2</sub>with Favorable Properties for SPECT Imaging of Colon Cancer

Tc-99m-Labeled Bombesin(7-14)Nh2 With Favorable Properties For Spect Imaging Of Colon Cancer